妇科肿瘤协作组(GCIG)第五届卵巢癌共识会议:罕见卵巢肿瘤的临床试验设计
本稿件报告了2015年11月东京第五届卵巢癌共识会议(OCCC)就罕见卵巢肿瘤临床试验设计达成的共识声明。会议围绕罕见上皮性卵巢癌(eOC)、性索间质肿瘤(SCST)和生殖细胞肿瘤(GCT)提出三个问题:罕见卵巢肿瘤特有的研究与试验问题、各瘤种应研究什么、随机试验是否可行,并给出相应共识。
要点
- 罕见卵巢肿瘤缺乏随机III期数据,难以定义对照臂,但存在值得研究的未满足需求。
- 应鼓励针对每种罕见卵巢肿瘤开展专门试验,相关时可按严格分层纳入eOC试验。
- 通过国际合作,罕见肿瘤的随机对照试验(RCT)应可行,已有试验显示在罕见eOC和SCST中可行。
核心结论
- 罕见卵巢肿瘤缺乏定义治疗标准的随机III期数据,使对照臂难以定义,但识别出值得研究的未满足需求。
- 国际商定的诊断标准、专家病理复核和转化研究至关重要。
- 应鼓励针对每种罕见卵巢肿瘤开展专门试验;相关问题下罕见eOC可按严格分层纳入eOC试验。
- 通过国际合作,RCT在任何罕见肿瘤中应可行;正在进行的试验已显示在罕见eOC和SCST中RCT可行。
研究设计与样本
- 稿件报告2015年11月在日本东京举行的第五届卵巢癌共识会议(OCCC)就罕见卵巢肿瘤临床试验设计达成的共识声明。
- 共识围绕罕见上皮性卵巢癌(eOC)、性索间质肿瘤(SCST)和生殖细胞肿瘤(GCT)提出三个问题:(i)罕见卵巢肿瘤特有的研究与试验问题;(ii)罕见eOC、GCT和SCST应研究什么;(iii)随机试验是否可行。
主要发现
- 罕见卵巢肿瘤缺乏定义治疗标准的随机III期数据,使对照臂难以定义,但识别出值得研究的未满足需求。
- 新出现的证据提示罕见eOC具有不同分子特征,但仍需试验为每种罕见eOC(透明细胞、低级别浆液性和黏液性)定义新的类型特异性标准。
- 对GCT,优先事项是在维持治愈率的同时降低治疗毒性;需要稳健的预后评分系统以及针对新发预后不良和复发GCT更有效的治疗。
- 对SCST,应识别经验证的预后标志物以及当前标准博来霉素/依托泊苷/顺铂(BEP)的替代方案。
- 正在进行的试验已显示在罕见eOC和SCST中RCT可行;黏液性卵巢癌可考虑按分层纳入非妇科黏液性肿瘤的RCT,高风险或复发GCT的RCT可作为男性和/或儿童生殖细胞研究的子集开展。
关键数值与推荐
- 国际商定的诊断标准、专家病理复核和转化研究至关重要。
- 应鼓励针对每种罕见卵巢肿瘤开展专门试验;相关问题下罕见eOC可按严格分层纳入eOC试验。
- 随机对照试验(RCT)应可通过国际合作在任何罕见肿瘤中开展。
- 黏液性卵巢癌可考虑按分层纳入非妇科黏液性肿瘤的RCT;高风险或复发GCT的RCT可作为男性和/或儿童生殖细胞研究的子集开展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This manuscript reports the consensus statements on designing clinical trials in rare ovarian tumours reached at the fifth Ovarian Cancer Consensus Conference (OCCC) held in Tokyo, November 2015. Three important questions were identified concerning rare ovarian tumours (rare epithelial ovarian cancers (eOC), sex-cord stromal tumours (SCST) and germ cell tumours (GCT)): (i) What are the research and trial issues that are unique to rare ovarian tumours? There is a lack of randomised phase III data defining standards of care which makes it difficult to define control arms, but identifies unmet needs that merit investigation. Internationally agreed upon diagnostic criteria, expert pathological review and translational research are crucial. (ii) What should be investigated in rare eOC, GCT and SCST? Trials dedicated to each rare ovarian tumour should be encouraged. Nonetheless, where the question is relevant, rare eOC can be included in eOC trials but with rigorous stratification. Although there is emerging evidence suggesting that rare eOC have different molecular profiles, trials are needed to define new type-specific standards for each rare eOC (clear cell, low grade serous and mucinous). For GCTs, a priority is reducing toxicities from treatment while maintaining cure rates. Both a robust prognostic scoring system and more effective treatments for de novo poor prognosis and relapsed GCTs are needed. For SCSTs, validated prognostic markers as well as alternatives to the current standard of bleomycin/etoposide/cisplatin (BEP) should be identified. (iii) Are randomised trials feasible? Randomised controlled trials (RCT) should be feasible in any of the rare tumours through international collaboration. Ongoing trials have already demonstrated the feasibility of RCT in rare eOC and SCST. Mucinous OC may be considered for inclusion, stratified, into RCTs of non-gynaecological mucinous tumours, while RCTs in high risk or relapsed GCT may be carried out as a subset of male and/or paediatric germ cell studies.
引用
- Leary AF, Quinn M, Fujiwara K, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. Ann Oncol. 2017. PMID: 27993794. doi:10.1093/annonc/mdw662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。